Research progress on drugs for diabetes based on insulin receptor/insulin receptor substrate

• Published in: Biochemical pharmacology 2023-11, Vol.217, p.115830-115830, Article 115830
• Main Authors: Su, Jingqian, Tang, Lu, Luo, Yingsheng, Xu, Jingran, Ouyang, Songying
• Format: Article
• Language: English
• Subjects: Diabetes drug; Diabetes mellitus; Insulin receptor; Insulin receptor substrate; Insulin resistance
• ISSN: 0006-2952; 1873-2968
• DOI: 10.1016/j.bcp.2023.115830

[Display omitted] The number of people with diabetes worldwide is increasing annually, resulting in a serious economic burden. Insulin resistance is a major pathology in the early onset of diabetes mellitus, and therefore, related drug studies have attracted research attention. The insulin receptor/insulin receptor substrate (INSR/IRS) serves as the primary conduit in the insulin signal transduction cascade, and dysregulation of this pathway can lead to insulin resistance. Currently, there exist a plethora of hypoglycemic drugs in the market; however, drugs that specifically target INSR/IRS are comparatively limited. The literature was collected by direct access to the PubMed database, and was searched using the terms “diabetes mellitus; insulin resistance; insulin receptor; insulin receptor substrate; diabetes drug” as the main keywords for literature over the last decade. This article provides a comprehensive analysis of the structure and function of INSR and IRS proteins, as well as the drugs used for the treatment of diabetes. Additionally, it serves as a valuable reference for the advancement of novel therapeutic agents for diabetes management.